Company Interview / Breathing new life into Australia's cannabis industry

Samuel Watson, CEO of Bioxyne (ASX: BXN) states the company is poised to lead Australia's cannabis industry. Through its Breath Life Sciences brand, Bioxyne (ASX: BXN) focuses on novel health products and reports a 190% revenue rise in the first quarter.

Samuel highlights Bioxyne's (ASX: BXN) strong position as one of the few TGA-licensed companies to manufacture diverse cannabis products, such as pastilles, gummies, and oils. He sees a first-mover advantage due to their scale in the growing $1 billion Australian market.

With several significant contracts secured, Samuel notes their facility's capacity is doubling. Bioxyne (ASX: BXN) plans to meet surplus demand from other manufacturers and maintain strong positive cash flow.